InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Discover the detailed record of transactions filed by Mann Brenda, VP of Research & Development. Officer active across 1 companies, notably Eyegate Pharmaceuticals INC. Aggregated, 14 filings have been published. The latest transaction was filed on 2 November 2021 — Retenue fiscale. Regulator: SEC (Form 4). All data is accessible without signup.
Declarations14 total
€10662 shares@ €1.7077.3% of flow
Common Stock
SEC:0001104659-21-133652·
€10662 shares@ €1.7073.0% of flow
Common Stock
SEC:0001104659-21-133652:0·
€10762 shares@ €1.737.4% of flow
Common Stock
SEC:0001104659-21-123266·
€10762 shares@ €1.733.0% of flow
Common Stock
SEC:0001104659-21-123266:0·
€9361 shares@ €1.5246.4% of flow
Common Stock
SEC:0001104659-21-112937·
€9361 shares@ €1.5242.6% of flow
Common Stock
SEC:0001104659-21-112937:0·
€12763 shares@ €2.0228.8% of flow
Common Stock
SEC:0001104659-21-100197·
€12763 shares@ €2.0223.6% of flow
Common Stock
SEC:0001104659-21-100197:0·
€481154 shares@ €3.123433.2% of flow
Common Stock
SEC:0001104659-21-089443·
€481154 shares@ €3.123413.5% of flow
Common Stock
SEC:0001104659-21-089443:0·
€535155 shares@ €3.453436.9% of flow
Common Stock
SEC:0001104659-21-077763·
€535155 shares@ €3.453415.1% of flow
Common Stock
SEC:0001104659-21-077763:0·
191 shares
Common Stock
SEC:0001104659-21-061946·
€657191 shares@ €3.437418.5% of flow
Common Stock
SEC:0001104659-21-061946:0·
14 of 14 declarations
About Mann Brenda
Brenda Mann is the Vice President of Research & Development at Eyegate Pharmaceuticals Inc. She is responsible for leading research and development initiatives aimed at innovating and improving the company's products.
